Get the Stockscreener App
3.94
8.54%
0.31
Kyverna Therapeutics Inc stock is traded at $3.94, with a volume of 217.38K.
It is up +8.54% in the last 24 hours and up +15.54% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$3.63
Open:
$3.68
24h Volume:
217.38K
Relative Volume:
0.54
Market Cap:
$170.39M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-1.2725
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
+6.20%
1M Performance:
+15.54%
6M Performance:
+48.12%
1Y Performance:
-48.02%
1-Day Range:
$3.60
$3.94
1-Week Range:
$3.55
$4.11
52-Week Range:
$1.78
$7.85
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.94 | 156.98M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Relative strength of Kyverna Therapeutics Inc. in sector analysis2025 Technical Overview & Safe Capital Growth Tips - Newser
Is Kyverna Therapeutics Inc. stock poised for growthMarket Volume Summary & High Conviction Buy Zone Picks - Newser
Strategies to average down on Kyverna Therapeutics Inc.Quarterly Portfolio Report & Verified High Yield Trade Plans - Newser
Wellington Management Group LLP Decreases Position in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Should you wait for a breakout in Kyverna Therapeutics Inc.July 2025 Patterns & Real-Time Volume Trigger Notifications - Newser
Understanding Kyverna Therapeutics Inc.’s price movement2025 Top Gainers & Daily Oversold Bounce Ideas - Newser
What technical models suggest about Kyverna Therapeutics Inc.’s comebackInsider Buying & Long Hold Capital Preservation Plans - Newser
New Remission Data on MG Patients Compelling - streetwisereports.com
Real time social sentiment graph for Kyverna Therapeutics Inc.July 2025 Pullbacks & Free Safe Capital Growth Stock Tips - Newser
Visual analytics tools that track Kyverna Therapeutics Inc. performanceJuly 2025 Catalysts & Community Consensus Stock Picks - Newser
Can swing trading help recover from Kyverna Therapeutics Inc. lossesMarket Trend Report & Community Verified Watchlist Alerts - Newser
Multi factor analysis applied to Kyverna Therapeutics Inc.2025 Retail Activity & Technical Buy Zone Confirmations - Newser
Aug Patterns: What’s Kyverna Therapeutics Inc.’s historical returnWeekly Stock Recap & Safe Entry Zone Identification - خودرو بانک
What’s the recovery path for long term holders of Kyverna Therapeutics Inc.Weekly Market Report & Community Consensus Picks - Newser
Leading vs lagging indicators on Kyverna Therapeutics Inc. performanceJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser
Published on: 2025-09-04 02:45:21 - Newser
Kyverna Therapeutics Inc. stock momentum explainedJuly 2025 Action & Smart Swing Trading Techniques - Newser
Published on: 2025-09-03 22:39:17 - Newser
Applying big data sentiment scoring on Kyverna Therapeutics Inc.Weekly Gains Summary & Long-Term Capital Growth Ideas - Newser
Kyverna Therapeutics Inc. stock retracement – recovery analysis2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Identifying reversal signals in Kyverna Therapeutics Inc.Exit Point & High Win Rate Trade Alerts - Newser
What does recent volatility data suggest for Kyverna Therapeutics Inc.Earnings Beat & Intraday High Probability Alerts - Newser
Will Kyverna Therapeutics Inc. bounce back from current supportNew Guidance & Free Accurate Trade Setup Notifications - Newser
Measuring Kyverna Therapeutics Inc.’s beta against major indicesJuly 2025 Market Mood & Precise Entry and Exit Recommendations - Newser
Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial - streetwisereports.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Consensus PT from Brokerages - MarketBeat
Is Kyverna Therapeutics Inc. benefiting from interest rate changesQuarterly Profit Review & AI Powered Buy/Sell Recommendations - خودرو بانک
Trend analysis for Kyverna Therapeutics Inc. this week2025 Price Momentum & Scalable Portfolio Growth Methods - Newser
Visual trend scoring systems applied to Kyverna Therapeutics Inc.Portfolio Value Summary & Consistent Profit Trading Strategies - Newser
Levels Update: What’s Kyverna Therapeutics Inc.’s historical returnEarnings Trend Report & Weekly High Potential Alerts - خودرو بانک
Will earnings trigger a reversal in Kyverna Therapeutics Inc.Portfolio Value Report & Stepwise Swing Trade Plans - Newser
How to read the order book for Kyverna Therapeutics Inc.Weekly Investment Report & Safe Entry Point Identification - Newser
Volume Summary: Can Kyverna Therapeutics Inc. outperform under higher oil pricesJuly 2025 Opening Moves & Safe Capital Investment Plans - خودرو بانک
What is the target price for Kyverna Therapeutics Inc. stockDollar Strength & Smart Money Movement Tracker - خودرو بانک
Market Trends: Is Kyverna Therapeutics Inc. stock risky to hold now2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - خودرو بانک
Kyverna Therapeutics Inc. stock prediction for this weekMarket Weekly Review & High Conviction Buy Zone Picks - Newser
Ranking Kyverna Therapeutics Inc. among high performing stocks via toolsJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
What is the earnings history of Kyverna Therapeutics Inc.2025 Macro Impact & Safe Swing Trade Setup Alerts - خودرو بانک
Can Kyverna Therapeutics Inc. outperform under higher oil pricesInflation Watch & AI Enhanced Trading Signals - خودرو بانک
‘FDA-aligned’ trial of KYV-101 for MG likely to start enrolling this year - Myasthenia Gravis News
Automated trading signals detected on Kyverna Therapeutics Inc.Dip Buying & AI Enhanced Trading Alerts - Newser
Is Kyverna Therapeutics Inc. stock risky to hold now2025 Risk Factors & Daily Market Momentum Tracking - خودرو بانک
Is Kyverna Therapeutics Inc. stock a good pick for beginnersTrade Performance Summary & Safe Entry Point Alerts - خودرو بانک
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):